What's the average weight loss on Mounjaro, and what does the trial evidence actually show?

What did SURMOUNT-1 actually measure, and how do the percentages translate to real weight?

SURMOUNT-1 randomised 2,539 adults with obesity (or overweight with at least one weight-related condition) who did not have type 2 diabetes. Participants received either tirzepatide or a placebo alongside a reduced-calorie diet and increased activity guidance over 72 weeks. At the 15mg dose, average body-weight reduction was around 20–21%. At 10mg it was approximately 19%, and at 5mg around 15%. The placebo group lost roughly 3%.

To put the top figure in concrete terms: a person starting at 100kg and losing 20% would reach around 80kg. Someone at 120kg would drop to approximately 96kg. The overall figures page breaks these calculations down further if you want to run your own numbers. What the percentage doesn't capture is the rate of that change, it accumulates across more than a year of weekly injections, with the steepest losses tending to occur in months two through six as the dose increases.

You may also see the figure cited as "up to ~22.5%" in some analyses. That reflects a secondary endpoint looking at participants who completed the full trial period per protocol rather than the primary intent-to-treat population. The 20–21% figure is the more conservative and more commonly cited number. NICE's appraisal of tirzepatide (TA1026) uses this evidence base when describing the medicine's effectiveness, and it forms part of why the treatment received a positive recommendation for NHS use in certain groups.

How quickly do people typically notice a difference on Mounjaro?

Most people notice some early change within the first two to four weeks, though this is rarely dramatic at the starter 2.5mg dose. The first pen's purpose is tolerability (letting your system adjust before the dose climbs) rather than producing rapid loss. Appetite suppression and a shift in how food feels are often the first things people report.

The rate of loss tends to accelerate from around weeks four to twelve as the dose moves up, and again after reaching the 7.5mg or 10mg level. Our page on how long Mounjaro takes to work covers the timeline in more detail. Week-one expectations are also worth reading if you're early in the process and wondering whether something is or isn't happening yet. The short version: the first few weeks are not the best indicator of what the medicine will eventually do.

Patience here is genuinely evidence-based, not just reassuring language. The 72-week trial duration exists precisely because meaningful loss accumulates over many months, not a handful of weeks. If you're frustrated that the numbers aren't moving as fast as you'd hoped, that's a very normal reaction, and one worth raising with your prescriber rather than interpreting as failure.

Does the figure change depending on which dose someone reaches?

Yes, clearly. SURMOUNT-1 showed a dose-dependent response: higher doses produced greater average weight reduction. This is why titration matters. Most people start at 2.5mg and increase every four weeks, with the prescriber guiding each step based on tolerability and response. Not everyone reaches 15mg (some find an effective balance at a lower maintenance level) and that's clinically normal. The trial's 5mg arm still showed average losses roughly five times greater than placebo.

It's also worth knowing that tirzepatide outperformed semaglutide 2.4mg (Wegovy's standard maintenance dose) in the SURMOUNT-5 head-to-head trial published in 2025. If you're comparing options, our tirzepatide weight-loss overview sits alongside the broader weight-loss treatments page and covers how the two medicines compare in practice. For context on what Mounjaro costs as a private treatment and what that price includes, the how to get Mounjaro online page is the clearest starting point.

How reliable are these trial numbers for predicting what someone will actually lose?

Trial averages describe a population under controlled conditions, standardised diet advice, regular check-ins, careful dose management. Individual outcomes spread considerably around those averages: some participants lost far more, others less. Factors including starting weight, metabolic health, adherence to lifestyle changes, how high a dose is tolerated and how long treatment continues all shape the result.

What the evidence does confirm is that for a significant proportion of adults, tirzepatide produces clinically meaningful weight loss at a scale that was previously only achievable through bariatric surgery. The weekly breakdown can give a more granular picture of how that trajectory typically looks.

Mounjaro is a prescription-only medicine. Treatment suitability depends on a clinical assessment, not a number you enter into a search engine. If you'd like to discuss whether the evidence translates to your situation, speaking to our prescribers is the right next step, the consultation is free, and a GPhC-registered prescriber reviews every application the same day.